Suppr超能文献

根据患有多种合并症和多种药物治疗的患者的明确和隐含标准,潜在不适当的处方。MULTIPAP:一项横断面研究。

Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study.

机构信息

Primary Healthcare Center General Ricardos, Madrid, Spain.

Medical Specialties and Public Health Department, School of Health Sciences, University Rey Juan Carlos Alcorcón, Madrid, Spain.

出版信息

PLoS One. 2020 Aug 12;15(8):e0237186. doi: 10.1371/journal.pone.0237186. eCollection 2020.

Abstract

BACKGROUND

Multimorbidity is a global health challenge that is associated with polypharmacy, increasing the risk of potentially inappropriate prescribing (PIP). There are tools to improve prescription, such as implicit and explicit criteria.

OBJECTIVE

To estimate the prevalence of PIP in a population aged 65 to 74 years with multimorbidity and polypharmacy, according to American Geriatrics Society Beers Criteria® (2015, 2019), the Screening Tool of Older Person's Prescription -STOPP- criteria (2008, 2014), and the Medication Appropriateness Index -MAI- criteria in primary care.

METHODS

This was an observational, descriptive, cross-sectional study. The sample included 593 community-dwelling elderly aged 65 to 74 years, with multimorbidity and polypharmacy, who participated in the MULTIPAP trial. Socio-demographic, clinical, professional, and pharmacological-treatment variables were recorded. Potentially inappropriate prescribing was detected by computerized prescription assistance system, and family doctors evaluated the MAI. The MAI-associated factors were analysed using a logistic regression model.

RESULTS

A total of 4,386 prescriptions were evaluated. The mean number of drugs was 7.4 (2.4 SD). A total of 94.1% of the patients in the study had at least one criterion for drug inappropriateness according to the MAI. Potentially inappropriate prescribing was detected in 57.7%, 43.6%, 68.8% and 71% of 50 patients according to the explicit criteria STOPP 2014, STOPP 2008, Beers 2019 and Beers 2015 respectively. For every new drug taken by a patient, the MAI score increased by 2.41 (95% CI 1.46; 3.35) points. Diabetes, ischaemic heart disease and asthma were independently associated with lower summated MAI scores.

CONCLUSIONS

The prevalence of potentially inappropriate prescribing detected in the sample was high and in agreement with previous literature for populations with multimorbidity and polypharmacy. The MAI criteria detected greater inappropriateness than did the explicit criteria, but their application was more complex and difficult to automate.

摘要

背景

多病共存是一个全球性的健康挑战,与多种药物治疗相关,增加了潜在不适当处方(PIP)的风险。有一些工具可以改善处方,例如隐含和明确的标准。

目的

根据美国老年医学会 Beers 标准®(2015 年、2019 年)、老年人处方筛选工具-STOPP-标准(2008 年、2014 年)和初级保健中的药物适宜性指数-MAI-标准,评估患有多病共存和多种药物治疗的 65 至 74 岁人群中 PIP 的患病率。

方法

这是一项观察性、描述性、横断面研究。样本包括参加 MULTIPAP 试验的 593 名 65 至 74 岁的社区居住老年人,患有多病共存和多种药物治疗。记录了社会人口统计学、临床、专业和药物治疗变量。通过计算机化处方辅助系统检测潜在不适当的处方,家庭医生评估 MAI。使用逻辑回归模型分析 MAI 相关因素。

结果

共评估了 4386 份处方。药物的平均数量为 7.4(2.4 标准差)。根据 MAI,研究中的患者中有 94.1%至少有一个药物不适当的标准。根据明确标准 STOPP 2014、STOPP 2008、Beers 2019 和 Beers 2015,50 名患者中有 57.7%、43.6%、68.8%和 71%分别检测到潜在不适当的处方。患者每服用一种新药,MAI 评分增加 2.41(95%置信区间 1.46;3.35)分。糖尿病、缺血性心脏病和哮喘与较低的总和 MAI 评分独立相关。

结论

样本中检测到的潜在不适当处方的患病率较高,与多病共存和多种药物治疗人群的先前文献一致。MAI 标准比明确标准检测到更多的不适当性,但它们的应用更复杂,难以实现自动化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e443/7423095/7f9047467729/pone.0237186.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验